scholarly journals Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Francisco Socola ◽  
Arturo Loaiza-Bonilla ◽  
Pasquale Benedetto

We report a case of a Caucasian male with a history of renal cell carcinoma metastatic (mRCC) to the lungs refractory despite aggressive treatment with several lines of targeted therapy. He was started on axitinib palliative targeted therapy with a good clinical and radiological response; however one month after treatment initiation he presented to the emergency department with severe dyspnea and hypoxemia. Physical exam and chest X-ray revealed left-sided tension pneumothorax which required emergent thoracostomy with subsequent improvement; however it recurred requiring video assisted thoracoscopy. A left-sided 4 × 3 cm cavitated necrotic lesion was found at the level of the main pulmonary artery. Repair with pericardial fat flap was performed. Surgical biopsies from this lesion revealed mRCC with extensive necrosis. Imaging studies before and after axitinib use showed an initial 4 × 3 cm mass seen in the same location of this large cavitated necrotic tumor. Pneumothorax has not been described as a potential major complication from the use of axitinib. Complete or near-complete responses of mRCC to axitinib targeted therapy may lead to this potential life-threatening complication, particularly if the metastatic lesions are located near to pleural structures. We also review pertinent clinical trial data on axitinib.

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Abhishek Bhat ◽  
Bruno Nahar ◽  
Vivek Venkatramani ◽  
Indraneel Banerjee ◽  
Oleksandr N. Kryvenko ◽  
...  

Renal cell carcinoma, particularly the most common clear cell type, is one of the most aggressive of urological cancers with significant risk of metastatic spread. It also has a propensity for venotropism with a proportion of tumors developing thrombi up to the right atrium. The response with newly adopted targeted therapy has been considered to be in the evolutionary stage with no clear role with respect to debulking or reducing the size of the inferior vena cava (IVC) thrombus. We describe a case of a right-sided metastatic RCC with Level IV thrombus initially managed with Pazopanib followed by Nivolumab and Adalimumab followed by cytoreductive nephrectomy and IVC thrombectomy in the post-targeted therapy setting with complete curative response.


2016 ◽  
Vol 70 (3) ◽  
pp. 469-475 ◽  
Author(s):  
Tomas Buchler ◽  
Zbynek Bortlicek ◽  
Alexandr Poprach ◽  
Tomas Pavlik ◽  
Veronika Veskrnova ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 143 ◽  
Author(s):  
Rohan Garje ◽  
Josiah An ◽  
Austin Greco ◽  
Raju Kumar Vaddepally ◽  
Yousef Zakharia

In the past two decades, there has been a significant improvement in the understanding of the molecular pathogenesis of Renal Cell Carcinoma (RCC). These insights in the biological pathways have resulted in the development of multiple agents targeting vascular endothelial growth factor (VEGF), as well as inhibitors of the mammalian target of the rapamycin (mTOR) pathway. Most recently, checkpoint inhibitors were shown to have excellent clinical efficacy. Although the patients are living longer, durable complete responses are rarely seen. Historically, high dose interleukin 2 (IL2) therapy has produced durable complete responses in 5% to 8% highly selected patients—albeit with significant toxicity. A durable complete response is a surrogate for a long-term response in the modern era of targeted therapy and checkpoint immunotherapy. Numerous clinical trials are currently exploring the combination of immunotherapy with various targeted therapeutic agents to develop therapies with a higher complete response rate with acceptable toxicity. in this study, we provide a comprehensive review of multiple reported and ongoing clinical trials evaluating the combination of PD-1/PD-L1 inhibitors with either ipilimumab (a cytotoxic T-lymphocyte-associated protein 4, CTLA-4 inhibitor) or with anti-VEGF targeted therapy.


2018 ◽  
Vol 25 (6) ◽  
pp. 528-533
Author(s):  
Dehua Liao ◽  
Dangang Shangguan ◽  
Dunwu Yao ◽  
Qing Zhu ◽  
Lizhi Cao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document